Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Hepion Pharmaceuticals, Inc. | a16-16629_1ex99d2.htm |
| EX-99.1 - EX-99.1 - Hepion Pharmaceuticals, Inc. | a16-16629_1ex99d1.htm |
| 8-K/A - 8-K/A - Hepion Pharmaceuticals, Inc. | a16-16629_18ka.htm |
Exhibit 23.1
Consent of Independent Auditors
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 No. 333-202625 and Form S-8 No.333-203867 of ContraVir Pharmaceuticals, Inc. of our report dated August 22, 2016, relating to the consolidated financial statements of Ciclofilin Pharmaceuticals, Inc. and Subsidiary (“Ciclofilin”), which appears in this Form 8-K/A of ContraVir Pharmaceuticals, Inc. Our report contains an explanatory paragraph regarding Ciclofilin’s ability to continue as a going concern.
/s/BDO USA, LLP
August 22, 2016